-
1.发明申请COMBINATION THERAPY WITH ANTI-CD74 AND ANTI-CD20 ANTIBODIES IN PATIENTS WITH RELAPSED AND REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA 审中-公开与抗CD74和抗CD20抗体联合治疗患有相关和耐药性B细胞非霍奇金淋巴瘤的患者公开(公告)号：US20160120976A1
公开(公告)日：2016-05-05
申请号：US14992528
申请日：2016-01-11
申请人： Immunomedics, Inc.
IPC分类号： A61K39/395 , A61K31/425 , A61K31/167 , A61K31/135 , A61K31/573 , A61K31/133
CPC分类号： A61K31/425 , A61K31/133 , A61K31/135 , A61K31/167 , A61K31/573 , A61K39/39558 , A61K47/6811 , A61K47/6849 , A61K47/6851 , A61K47/6885 , A61K51/1027 , A61K51/1045 , A61K2039/505 , A61K2039/507 , A61K2039/545 , C07K14/47 , C07K16/2803 , C07K16/2833 , C07K16/2887 , C07K2317/24 , C07K2317/31 , C07K2317/55 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/90 , C07K2319/55 , C07K2319/70 , A61K2300/00
摘要： The present invention concerns methods of treating relapsed/resistant non-Hodgkin's lymphoma using combination therapy with an anti-CD20 antibody or fragment and an anti-CD74 antibody or fragment. In preferred embodiments, the antibody combination is administered along with at least one other therapeutic agent. The combination is effective to treat indolent NHL that is resistant to or relapsed from at least one therapy for NHL, including but not limited to rituximab resistant NHL. The antibody combination may be administered to human subjects at specific dosages and dosing schedules, that are effective to treat the disease but do not induce a dose-limiting toxicity.
摘要翻译： 本发明涉及使用与抗CD20抗体或片段和抗-CD74抗体或片段的组合疗法治疗复发/抗性非霍奇金淋巴瘤的方法。 在优选的实施方案中，抗体组合与至少一种其它治疗剂一起施用。 该组合可有效治疗对至少一种NHL治疗有耐药或复发的无痛NHL，包括但不限于利妥昔单抗耐药性NHL。 抗体组合可以以特定剂量和给药方案施用于人受试者，其有效治疗疾病，但不诱导剂量限制性毒性。
-
2.发明申请SUBCUTANEOUS ADMINISTRATION OF ANTI-CD74 ANTIBODY FOR SYSTEMIC LUPUS ERYTHEMATOSUS AND AUTOIMMUNE DISEASE 审中-公开用于系统性红斑狼疮和自发性疾病的抗CD74抗体的免疫应答公开(公告)号：US20160279239A1
公开(公告)日：2016-09-29
申请号：US15131655
申请日：2016-04-18
申请人： Immunomedics, Inc.
IPC分类号： A61K39/395 , A61K45/06 , A61K47/26 , A61K9/08 , A61K47/12 , A61K47/02 , C07K16/28 , A61K9/00
CPC分类号： A61K39/3955 , A61K9/0019 , A61K9/08 , A61K39/39558 , A61K39/39591 , A61K45/06 , A61K47/6879 , A61K47/6897 , A61K51/088 , A61K2039/505 , B82Y5/00 , C07K16/065 , C07K16/2803 , C07K16/2833 , C07K16/2851 , C07K16/2887 , C07K16/2896 , C07K16/30 , C07K16/3069 , C07K2317/24 , C07K2317/31 , C07K2317/51 , C07K2317/515 , C07K2317/52 , C07K2317/56 , C07K2317/76 , C07K2317/94
摘要： Disclosed are methods, compositions and uses of concentrated formulations of anti-CD74 antibody, of use for treating autoimmune diseases. In a specific non-limiting embodiment, the autoimmune disease is systemic lupus erythematosus (SLE). In a preferred embodiment, the anti-CD74 antibody is milatuzumab (IMMU-115). The antibody is administered subcutaneously, preferably at a dosage of 250 mg once a week for four weeks. The subcutaneous administration of anti-CD74 antibody ameliorates the symptoms of autoimmune diseases, with only manageable side effects.
摘要翻译： 公开了用于治疗自身免疫疾病的抗CD74抗体的浓缩制剂的方法，组合物和用途。 在具体的非限制性实施方案中，自身免疫性疾病是系统性红斑狼疮（SLE）。 在优选的实施方案中，抗CD74抗体是米他珠单抗（IMMU-115）。 抗体经皮下施用，优选以250mg的剂量每周一次，持续四周。 抗CD74抗体的皮下给药改善了自身免疫性疾病的症状，只有可控的副作用。
-
3.发明申请公开(公告)号：US20180162945A1
公开(公告)日：2018-06-14
申请号：US15868704
申请日：2018-01-11
申请人： Immunomedics, Inc.
IPC分类号： C07K16/28 , A61K9/08 , A61K39/395 , A61K45/06 , C07K16/06 , A61K9/00 , C07K16/30 , B82Y5/00 , A61K39/00
CPC分类号： C07K16/2833 , A61K9/0019 , A61K9/08 , A61K39/3955 , A61K39/39591 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61K2039/54 , A61K2039/545 , A61K2039/552 , B82Y5/00 , C07K16/065 , C07K16/2803 , C07K16/2851 , C07K16/2887 , C07K16/2896 , C07K16/30 , C07K16/3069 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/51 , C07K2317/515 , C07K2317/52 , C07K2317/53 , C07K2317/56 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/92 , C07K2317/94
摘要： The present invention concerns compositions and methods of use of anti-HLA-DR antibodies or fragments thereof. In preferred embodiments, the antibodies are subcutaneously administered to a human patient with a hematologic cancer or autoimmune disease. The subcutaneously administered anti-HLA-DR antibody is effective to treat hematologic cancer or autoimmune disease in patients that have relapsed from or are refractory to standard therapies for hematologic cancer or autoimmune disease, such as administration of anti-CD20 antibodies, such as rituximab.
-
4.发明申请公开(公告)号：US20170266281A1
公开(公告)日：2017-09-21
申请号：US15601458
申请日：2017-05-22
申请人： Immunomedics, Inc.
IPC分类号： A61K39/395 , A61K45/06 , A61K51/08 , A61K9/00 , A61K9/08 , B82Y5/00 , C07K16/06 , C07K16/28 , C07K16/30 , A61K39/00
CPC分类号： A61K39/3955 , A61K9/0019 , A61K9/08 , A61K39/39558 , A61K39/39591 , A61K45/06 , A61K47/6879 , A61K47/6897 , A61K51/088 , A61K2039/505 , B82Y5/00 , C07K16/065 , C07K16/2803 , C07K16/2833 , C07K16/2851 , C07K16/2887 , C07K16/2896 , C07K16/30 , C07K16/3069 , C07K2317/24 , C07K2317/31 , C07K2317/51 , C07K2317/515 , C07K2317/52 , C07K2317/56 , C07K2317/76 , C07K2317/94
摘要： Disclosed are methods, compositions and uses of concentrated formulations of anti-CD74 antibody, of use for treating autoimmune diseases. In a specific non-limiting embodiment, the autoimmune disease is systemic lupus erythematosus (SLE). In a preferred embodiment, the anti-CD74 antibody is milatuzumab (IMMU-115). The antibody is administered subcutaneously, preferably at a dosage of 250 mg once a week for four weeks. The subcutaneous administration of anti-CD74 antibody ameliorates the symptoms of autoimmune diseases, with only manageable side effects.
-
公开(公告)号：US11180559B2
公开(公告)日：2021-11-23
申请号：US15868704
申请日：2018-01-11
申请人： Immunomedics, Inc.
IPC分类号： A61K39/00 , C07K16/28 , C07K16/30 , A61K39/395 , A61K9/00 , A61K45/06 , A61K9/08 , C07K16/06 , B82Y5/00
摘要： The present invention concerns compositions and methods of use of anti-HLA-DR antibodies or fragments thereof. In preferred embodiments, the antibodies are subcutaneously administered to a human patient with a hematologic cancer or autoimmune disease. The subcutaneously administered anti-HLA-DR antibody is effective to treat hematologic cancer or autoimmune disease in patients that have relapsed from or are refractory to standard therapies for hematologic cancer or autoimmune disease, such as administration of anti-CD20 antibodies, such as rituximab.
-
公开(公告)号：US10322176B2
公开(公告)日：2019-06-18
申请号：US15601458
申请日：2017-05-22
申请人： Immunomedics, Inc.
IPC分类号： A61K39/395 , C07K16/28 , A61K45/06 , A61K51/08 , B82Y5/00 , C07K16/06 , C07K16/30 , A61K47/68 , A61K9/00 , A61K9/08 , A61K39/00
摘要： Disclosed are methods, compositions and uses of concentrated formulations of anti-CD74 antibody, of use for treating autoimmune diseases. In a specific non-limiting embodiment, the autoimmune disease is systemic lupus erythematosus (SLE). In a preferred embodiment, the anti-CD74 antibody is milatuzumab (IMMU-115). The antibody is administered subcutaneously, preferably at a dosage of 250 mg once a week for four weeks. The subcutaneous administration of anti-CD74 antibody ameliorates the symptoms of autoimmune diseases, with only manageable side effects.
-
7.发明申请SUBCUTANEOUS ANTI-HLA-DR MONOCLONAL ANTIBODY FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES 审中-公开用于治疗血液恶性肿瘤的抗体HLA-DR单克隆抗体公开(公告)号：US20160355591A1
公开(公告)日：2016-12-08
申请号：US15240052
申请日：2016-08-18
申请人： Immunomedics, Inc.
CPC分类号： C07K16/2833 , A61K9/0019 , A61K9/08 , A61K39/3955 , A61K39/39591 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61K2039/54 , A61K2039/545 , A61K2039/552 , B82Y5/00 , C07K16/065 , C07K16/2803 , C07K16/2851 , C07K16/2887 , C07K16/2896 , C07K16/30 , C07K16/3069 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/51 , C07K2317/515 , C07K2317/52 , C07K2317/53 , C07K2317/56 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/92 , C07K2317/94
摘要： The present invention concerns compositions and methods of use of anti-HLA-DR antibodies or fragments thereof. In preferred embodiments, the antibodies are subcutaneously administered to a human patient with a hematologic cancer or autoimmune disease. The subcutaneously administered anti-HLA-DR antibody is effective to treat hematologic cancer or autoimmune disease in patients that have relapsed from or are refractory to standard therapies for hematologic cancer or autoimmune disease, such as administration of anti-CD20 antibodies, such as rituximab.
摘要翻译： 本发明涉及使用抗HLA-DR抗体或其片段的组合物和方法。 在优选的实施方案中，将抗体皮下施用于具有血液学癌症或自身免疫疾病的人类患者。 皮下施用的抗HLA-DR抗体可有效治疗由血液学癌症或自身免疫性疾病的标准治疗复发或难以治疗的患者的血液癌症或自身免疫性疾病，例如施用抗CD20抗体如利妥昔单抗。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.022 秒)
